Literature DB >> 12714818

Biochemical and clinical aspects of methotrexate neurotoxicity.

Sandra Vezmar1, Achim Becker, Udo Bode, Ulrich Jaehde.   

Abstract

Acute, subacute and chronic neurotoxicity have been observed after the administration of high-dose and/or intrathecal methotrexate (MTX). Acute toxicity is usually transient without permanent damage. Subacute and chronic toxicity are associated with changes in the brain and/or the spinal cord which may be progressive and even lead to coma and death in severe cases. It is believed that MTX can induce direct toxic effects to the CNS by damaging the neuronal tissue. Moreover, MTX interferes with the metabolic pathways of folates, excitatory amino acids, homocysteine, S-adenosylmethionine/S-adenosylhomocysteine, adenosine and biopterins, inducing biochemical alterations which have been associated with neurotoxic symptoms. It has been suggested that acute toxicity is partly mediated by adenosine, whereas homocysteine, S-adenosylmethionine/S-adenosylhomocysteine, excitatory amino acids and biopterins may play an important role in the development of subacute and chronic toxicity. A better understanding of the pathogenesis of MTX neurotoxicity would offer the possibility of developing new therapeutic strategies for its treatment or prevention. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714818     DOI: 10.1159/000069773

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  53 in total

1.  Acute pseudobulbar palsy due to methotrexate with rapid response to intravenous immunoglobulin.

Authors:  P Kinirons; A Fortune; H Enright; R P J Murphy
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

2.  Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors.

Authors:  Itzik Cooper; David Last; David Guez; Shirley Sharabi; Shirin Elhaik Goldman; Irit Lubitz; Dianne Daniels; Sharona Salomon; Gregory Tamar; Tzur Tamir; Ronni Mardor; Mati Fridkin; Yoram Shechter; Yael Mardor
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-11       Impact factor: 6.200

3.  Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles.

Authors:  Conroy Sun; Chen Fang; Zachary Stephen; Omid Veiseh; Stacey Hansen; Donghoon Lee; Richard G Ellenbogen; Jim Olson; Miqin Zhang
Journal:  Nanomedicine (Lond)       Date:  2008-08       Impact factor: 5.307

4.  Letters to the editor.

Authors: 
Journal:  Ochsner J       Date:  2013

5.  Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.

Authors:  M E Haykin; M Gorman; J van Hoff; R K Fulbright; J M Baehring
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

6.  Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.

Authors:  Silas W Smith; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2008-06

7.  Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire).

Authors:  Nibah Fatimah; Babur Salim; Amjad Nasim; Kamran Hussain; Harris Gul; Sarah Niazi
Journal:  Clin Rheumatol       Date:  2016-04-06       Impact factor: 2.980

8.  Methotrexate leukoencephalopathy mimics acute progressive stroke.

Authors:  Ryota Tanaka; Kumi Sasaki-Ikesawa; Hideki Shimura; Kenya Nishioka; Nobutaka Hattori; Shigeki Tanaka
Journal:  J Neurol       Date:  2011-04-22       Impact factor: 4.849

Review 9.  [White matter alterations after chemotherapy and radiation].

Authors:  A Simgen
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

10.  Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.